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Purpose: To investigate the associations of metabolite levels derived from magnetic
resonance spectroscopic imaging (MRSI) and 18F-fluciclovine positron emission
tomography (PET) with prostate tissue characteristics.
Methods: In a cohort of 19 high-risk prostate cancer patients that underwent
simultaneous PET/MRI, we evaluated the diagnostic performance of MRSI and PET
for discrimination of aggressive cancer lesions from healthy tissue and benign lesions.
Data analysis comprised calculations of correlations of mean standardized uptake values
(SUVmean), maximum SUV (SUVmax), and the MRSI-derived ratio of (total choline +
spermine + creatine) to citrate (CSC/C). Whole-mount histopathology was used as gold
standard.
Results: The results showed a moderate significant correlation between both SUVmean
and SUVmax with CSC/C ratio.
Conclusions: We demonstrated that the simultaneous acquisition of 18F-fluciclovine
PET and MRSI with an integrated PET/MRI system is feasible and a combination of these
imaging modalities has potential to improve the diagnostic sensitivity and specificity of
prostate cancer lesions.
Keywords: positron emission tomography, magnetic resonance spectroscopy, benign prostatic hyperplasia,
chemical shift imaging, citrate, prostate cancer
INTRODUCTION
Prostate cancer is one of the most commonly diagnosed cancers and among the leading causes
of cancer-related deaths in men worldwide (1). The disease can be relatively indolent due to
its slow growth, and there is a great need for reliable methods to identify cases of aggressive
disease. Multi-parametric magnetic resonance imaging (mpMRI) has emerged as an important
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tool in the detection, localization, and characterization of
prostate cancer (2–4). Guidelines recommend to include
morphologic T2-weighted and functional imaging (such as
diffusion-weighted MRI and dynamic contrast-enhanced MRI)
in diagnostic mpMRI protocols for prostate cancer (5). In
addition, MR offers possibilities to obtain information on
tissue content of certain metabolites through proton magnetic
resonance spectroscopic imaging (MRSI). This functional
imaging technique can non-invasively detect and quantify
metabolites in the prostate, such as choline-containing molecules
(tCho), spermine, creatine, and citrate. Increased tCho and
decreased citrate and spermine levels are associated with prostate
cancer (6). Previous studies have demonstrated a significant
correlation between prostate cancer aggressiveness, represented
by the histopathological Gleason score (7), and decreased levels
of citrate (a Krebs cycle and fatty acid synthesis intermediate,
accumulating in luminal space) and spermine accompanied by
an increased level of tCho which is involved in phospholipid
metabolism (8–11). The metabolite ratio (tCho + spermine +
creatine)/citrate is often used as an in vivo biomarker for prostate
cancer (6, 8–10, 12). Interestingly, a recent in vivo MRSI study
demonstrated that the number of voxels with undetectable levels
of polyamines was associated with recurrence (13), which is in
accordance with ex vivomeasurements showing that low levels of
spermine and citrate in prostate cancer tissue are associated with
recurrence (14).
Functional information of prostate cancer can also be
obtained by positron emission tomography (PET) with several
tracers (15). High-resolution anatomical imaging provided by
MRI combined with landmarks elucidated by PET can improve
localization of prostate cancer lesions (16–18). The combination
of PET imaging with the amino acid analog anti-1-amino-3-18F-
perfluorocyclobutane-1-carboxylic acid (18F-fluciclovine) and
anatomical MR imaging is promising for detection of prostate
cancer lesions (19, 20). Despite significant differences in the 18F-
fluciclovine uptake between prostate cancer and normal prostate
tissue, there is an overlap of the uptake between cancer tissue and
benign lesions, occurring, e.g., in benign prostatic hyperplasia
(BPH) (19). Similarly, elevated choline levels detected by either
18F-flurocholine PET, 11C-choline PET, or MRSI can introduce
ambiguity in the interpretation of lesion/BPH characteristics (15,
21) With an integrated PET/MR scanner, MRSI and PET images
can be acquired simultaneously, which potentially provides
complementary information on prostate cancer metabolism.
This study aimed to simultaneously measure 18F-fluciclovine
and MRSI-visible metabolites in patients with high-risk prostate
cancer, examine the correlations between PET and MRSI and to
assess their combined diagnostic performance for cancer lesion
localization.
MATERIALS AND METHODS
Patients
We selected 19 out of 28 patients from a previously reported
study cohort (19, 20, 22), for whom MRSI data were acquired
as part of an extensive PET/MRI protocol. Results from
the MRSI data of this cohort have not been previously
reported. These 19 patients [median (range) age of 66
(55–72) years] had biopsy-proven high-risk prostate cancer
(Gleason score ≥ 8 and/or a prostate-specific antigen (PSA)
≥ 20 ng/mL, and/or clinical T-stage ≥ cT3). All patients
were scheduled for robot-assisted radical prostatectomy (RARP)
with extended pelvic lymph node dissection (ePLND). In
the current study, we investigated the diagnostic power of
combined 18F-fluciclovine PET/MRSI for loco-regional detection
and localization of primary prostate cancer (ClinicalTrials.gov;
identifier NCT02076503). The study was approved by our
institution (St. Olavs Hospital, Trondheim University Hospital)
and the Regional Committee for Medical and Health Research
Ethics, central Norway (identifier 2013/1513). All patients
provided written informed consent before participation in this
study.
Imaging Protocol
Imaging was performed on an integrated 3.0T PET/MRI system
(Magnetom Biograph mMR, Siemens Healthineers, Erlangen,
Germany). The PET tracer 18F-fluciclovine was produced by
the Norwegian Medical Cyclotron Center in Oslo by methods
previously described (23). The PET/MRI protocol consisted of a
full clinical mpMRI examination, combined with simultaneous
PET imaging. The anatomical MR images were acquired in
two-bed positions, covering from the ureteral crossing of the
common iliac vessels to the pelvic floor (19). We acquired a total
of 45min of sequential list-mode PET data for analysis of the
tracer dynamics in the prostate. In a recent study from the same
patient cohort, we concluded that the (late)-window PET imaging
protocol can easily be combined with the MR protocols (19).
Therefore, we restricted the MRSI-combined PET evaluation
to the PET-derived values from that time point. MRSI data
was obtained, using spine coil elements and the MR body coil
(Magnetom Biograph mMR, Siemens Healthineers, Erlangen,
Germany) with a standard PRESS sequence with dual-frequency
water and lipid suppression at TR/TE=750/145ms (24), FOV
= 84 × 84 × 70 cm3, acquisition matrix size of 12 × 12 × 10
interpolated into 16 × 16 × 16, spectral bandwidth of 1,250Hz,
512 complex points, 6 averages, weighted k-space sampling was
used followed by post-acquisition k-space Hamming filtering,
measurement time of 9min 54 s, and outer volume suppression
slices positioned around the prostate.
Image Analysis
MRSI Analysis
Spectral data were analyzed using the Java-based software jMRUI
v5.2 (http://www.jmrui.eu/), and the spectral peaks were fitted
with Lorentzian lines using AMARES (24). This software plots
the original signal, the estimated fit, and the residuals (derived
from subtracting the estimated spectrum fit from the original
spectrum), which can be inspected visually by an expert. We
determined the signal-to-noise ratio (SNR) by the peak intensity
of the fitted signal integral for tCho, spermine, and creatine
as the signal and the standard deviation of spectral region 8–
9 ppm (without signal) for the noise. Spectra with a sufficient
signal-to-noise ratio (SNR> 2), adequate phasing, and absence of
baseline distortions were selected for analysis. The intensities of
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the overlapping signals of tCho, spermine and creatine correlated
negatively with each other (r <−0.4), which is why only the sum
of these intensities is reported. Hence, the total spectral intensity
of the resonances from tCho, spermine, and creatine between
3.0 and 3.22 ppm was expressed as Choline+Spermine+Creatine
(CSC). The citrate peaks were modeled as four single Lorentzian
peaks with midpoint and difference in chemical shifts of 2.62
and 0.15 ppm, respectively. Equal line width for all peaks of
citrate was determined. This prior knowledge led to the smallest
residuals for all metabolite resonances (Figure 1). The metabolite
ratio of CSC/Citrate (C) was generated voxel-wise.
PET Analysis
PET images were reconstructed from the list-mode data acquired
33 to 38min after tracer injection, as previously described (19).
Standardized uptake values (SUV) were linearly interpolated to
overlay on both the corresponding T2-weighted MR image and
the MRSI voxel matrix. PET images were reconstructed on a
344 × 344 matrix with 2.1 × 2.1mm in plane resolution and
2mm slice thickness. The nominal MRSI voxels were larger than
the nominal PET voxels, as obtained after reconstruction, so
that 16 PET voxels fitted into 1 MRSI voxel. The mean and
maximum SUV values of these 16 voxels were calculated, giving
the SUVmean and SUVmax per MRSI voxel (Figure 2).
Surgery And Histopathology
RARP with ePLND was performed according to EAU guidelines
(25). The resected prostate gland was serially sectioned from
apex to base in 4mm thick slices perpendicular to the urethra.
The most inferior slice (apex) and most superior slice (base)
were additionally sectioned in the longitudinal direction for
optimal histopathological evaluation of extracapsular extension.
All slices were embedded in paraffin before 3.5µm thick sections
FIGURE 1 | Example of a proton MR spectrum (solid line) of one voxel in
healthy prostate tissue with the overlaid spectrum fit (red dash line) and the
residuals (blue dash-dot line). tCho, total choline; Spr, spermine; Cre, creatine;
Cit, citrate.
were cut for staining with hematoxylin and eosin. A pathologist
specialized in uropathology outlined cancer foci and regions
of BPH and inflammation and described cancer Gleason grade
scoring (7) on whole-mount histopathology slides.We used these
slides to identify the underlying tissue content (cancer, BPH, or
normal tissue) of the selected spectroscopy voxels by visually
matching them with the corresponding slice of T2-weighted MR
images.
Statistical Analysis
Statistical analyses were performed using SPSS (IBM SPSS
Statistics 24.0). To investigate relationships between the results
from PET and MRSI data, we performed a correlation analysis
including linear mixed model (LMM) corrections. LMM was
used to correct for multiple measures per subject which may
introduce multiple intercepts when including data from all
individuals. The threshold for statistical significance was defined
as p ≤ 0.05. We also performed receiver operating characteristic
(ROC) curve analysis to evaluate the performance of metabolite
ratio CSC/C, SUVmean, SUVmax, and a combination of all
covariates in discrimination between the voxels determined as
either tumor or combined BPH and healthy tissue. The combined
covariates were generated in SPSS, by estimating a logistic
regression model of the variables to predict the probability
from that model (26). The predicted probability served as input
to ROC analysis. The area under the ROC curve (AUC) was
calculated as a measure of performance. The ROC analysis
was performed using MedCalc Statistical Software version 17.6
(MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.
org; 2017).
RESULTS
The included patients (n = 19) had a median (range) PSA level
of 15.4 (3.7–56.9) ng/mL, median (range) biopsy Gleason grade
group of 5 (1–5) and their pathological T-stage ranged from cT2b
to cT3b (Table 1). In total 196 (23%) spectroscopic voxels (from
859 available voxels) were eligible for analysis with sufficient
signal-to-noise (on average 10 voxels per patient). MRSI voxels
were categorized as representing either healthy, BPH, or tumor
tissue (Table 1) based on histology examinations. The metabolic
ratio (CSC/C) derived from MRSI was significantly correlated
with both SUVmean (R = 0.42, p < 0.0001) and SUVmax (R
= 0.44, p < 0.0001) (Figure 3). The results of ROC analysis
showed that neither MRSI nor PET performed better than
the other technique alone in distinguishing tumor voxels from
other voxels (healthy and BPH). The AUC of the ROC curves
for CSC/C, SUVmean, and SUVmax did not differ significantly
but were significantly higher than unity (50%) line (Figure 4).
Importantly, the combination of all imaging variables provided
a higher AUC value than the AUC values derived from the
individual ROCs (p < 0.05).
DISCUSSION
PET/MRI offers a powerful imaging tool for high-risk prostate
patients, providing simultaneous high-resolution MRI and
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FIGURE 2 | Representative PET, MRI, and MRSI in a 66-year-old patient with prostate specific antigen 3.7 ng/mL, clinical stage T3b and Gleason score 4+5 (Grade
group 5). (A) 18F-fluciclovine image shows a focal uptake in the right lobe of the peripheral zone of the prostate; (B) Axial T2-weighted MR image, overlaid MRSI grid
box and the matching whole-mount histology slice, demonstrating the lesion distribution in the selected slice. (C) MR spectra from the red color voxels in B- only
voxels with sufficient spectral quality for analysis are displayed. PET, positron emission tomography; MRSI, Magnetic resonance spectroscopic imaging; CCS, total
choline + creatine + spermine; Cit, citrate.
TABLE 1 | Summary of the patients clinical variables and included MRSI voxels.
Patient Age PSA (ng/mL) Gleason grade group from
diagnostic biopsies (1-5)
Pathological T-stage Total #MRSI voxels (included) MRSI voxel H/B/T Prostate zone
1 69 15.4 5 T3b 41 (16) 15/0/1 TZ&PZ/-/PZ
2 71.3 10.7 5 T3b 52 (17) 6/10/1 TZ/TZ/PZ
3 71.9 7.8 5 T2c 39 (8) 4/3/1 TZ/TZ/PZ
4 64.4 15.4 2 T3a 34 (3) 2/0/1 TZ/-/PZ
5 62.7 26 2 T3a 48 (4) 2/1/1 TZ/TZ/PZ&TZ
6 63.9 11.7 5 T3a 50 (8) 6/0/2 TZ/-/PZ
7 68.8 10.8 5 T3b 48 (9) 5/3/1 TZ/-/PZ
8 65.8 3.7 4 T3b 54 (18) 10/4/4 TZ/TZ/PZ&TZ
9 69.8 27.4 5 T3b 39 (9) 2/0/7 TZ/-/PZ&TZ
10 71.5 15.9 5 T3a 58 (7) 2/0/5 TZ/-/PZ&TZ
11 67.1 5.8 4 T3b 39 (9) 2/0/7 TZ/-/PZ&TZ
12 63.3 45.5 2 T3b 55 (7) 5/0/2 TZ/-/PZ
13 64.9 23.5 1 T4 58 (16) 5/0/11 TZ/-/PZ&TZ
14 55 8.6 5 T3b 30 (3) 2/0/1 TZ/-/PZ
15 70.7 33.4 5 T3a 38 (4) 0/0/4 -/-/PZ&TZ
16 65.9 11.2 4 T3b 49 (18) 8/0/10 TZ/-/PZ&TZ
17 61.6 6.3 4 T2c 33 (10) 8/0/2 TZ/-/TZ
18 69 56.9 2 T2c 46 (19) 12/4/3 TZ/TZ/PZ
19 66.4 17.4 5 T2c 48 (11) 9/0/2 TZ/-/PZ
H/B/T, Healthy/BPH(benign prostatic hyperplasia)/Tumor; CZ, central zone; PZ, peripheral zone; TZ, transition zone.
functional PET imaging (2). This pilot study is the first to
present an initial evaluation of the diagnostic performance of
combined metabolic imaging markers, uptake of PET tracer
18F-fluciclovine and CSC/C ratio, in high-risk prostate cancer.
We demonstrate that the simultaneous acquisition of 18F-
fluciclovine PET and MRSI with an integrated PET/MRI system
in patients with prostate cancer is feasible. The results showed a
moderate, yet significant correlation between PET tracer uptake
(SUVmean and SUVmax) and the spectroscopic CSC/C ratio.
A combination of the imaging outcomes derived from the
integrated PET and MRSI modalities substantially improved the
discrimination between cancer and non-cancer tissues in the
prostate.
Amino acids are considered essential nutrients for growth and
maintenance, as well as for cell signaling in tumor cells. F18-
fluciclovine is a synthetic analog of leucine, an essential amino
acid involved in the biosynthesis of proteins. Leucine promotes
protein synthesis via the phosphorylation of the mechanistic
target of rapamycin (mTOR), a protein kinase that regulates
cell growth (27). Also, leucine plays a key role in cellular
energy metabolism by promoting glucose uptake, mitochondrial
biogenesis, and fatty acid oxidation (28, 29). The uptake of
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FIGURE 3 | Correlation analysis between the metabolite ratio CSC/C [(total choline + spermine + creatine)/citrate] and SUVmean (left) and SUVmax (right).
FIGURE 4 | Receiver operating characteristic (ROC) curve analysis was
performed as a measure for the performance of the metabolite ratio CSC/C,
SUVmean, SUVmax, and a combination of all covariates in discrimination of
tumors from the combined BPH and healthy tissues. The area under the ROC
curve (AUC) was calculated as a measure of performance. MRSI and SUV
parameters provide quite similar AUCs in separating voxels from tumor vs. all
the other tissues. All AUCs were statistically significantly different from 50%
threshold (p < 0.001). A combination of all imaging parameters (dashed line)
provided a statistically significantly higher AUC than all the individual
parameters (solid lines, p < 0.05).
PET tracer 18F-fluciclovine in prostate cancer can thus be
partly explained by the increased cancer cell demands and the
cross-talk between protein synthesis and energy metabolism.
18F-fluciclovine biodistribution studies have demonstrated a
relatively low renal excretion and bladder activity of this
radiotracer, and it is therefore considered a suitable biomarker for
prostate PET imaging (30, 31). Several studies have investigated
the performance of 18F-fluciclovine PET in prostate cancer,
demonstrating that the tracer uptake is significantly higher in
prostate tumors than benign tissues (23, 32). In a study of 89
patients with biochemically recurrent prostate cancer, Nanni and
colleagues demonstrated a superior diagnostic performance of
18F-fluciclovine to 11C-choline (33). However, the tracer has
also showed a non-specific uptake related to BPH (34). This
pitfall can hamper the primary tumor localization. Previous
results have demonstrated a significant contribution of SUVmax
in distinguishing between the tumor and normal prostate, while
SUVmean was not significantly different from that of the tumor
and BPH (35).
Choline metabolites are key precursors in the biosynthesis
of phospholipids in cell membranes. The rapid proliferation
of cancer cells induces an increased phospholipid demand,
which is considered as an important reason for tCho elevation.
Normal and non-cancerous prostate cells produce, and secrete a
significant amount of citrate into the luminal space of the gland.
It has been demonstrated that the decreased level of citrate is
associated with prostate cancer (36, 37). The resonance of citrate
is well-resolved from the other metabolite signals, but those of
tCho, spermine, and creatine often overlap in 1H MR spectra
of the prostate, in particular, if obtained by a common PRESS
sequence (38, 39). Therefore, quantification of the individual
metabolite signals can be challenging in this resonance region,
and in quantitative evaluations the sum of the estimated peak fit
integrals for the latter three metabolites is used instead.
In this study, we demonstrate that combined PET/MRSI may
be meaningful in certain subgroups of patients such as high-
risk prostate cancer patients. The application may facilitate the
indication of a more aggressive region in the prostate tumor,
determine target for guided biopsy, and localization of the most
aggressive region for focal treatment. Challenges in the clinical
use of the MRSI technique is the robustness of the acquisition
methods and lack of proper software for automatic analysis of
the MR spectra. Recently, we have demonstrated that by applying
Frontiers in Oncology | www.frontiersin.org 5 November 2018 | Volume 8 | Article 516
Esmaeili et al. Hybrid PET/MRSI of Prostate Cancer
adiabatic pulses in the acquisition its robustness and spectral
quality are substantially improved over the common PRESS
acquisitionmethod as applied in this study. The improved quality
also facilitates a better spectral analysis (39, 40). The ability to
acquire PET and MR data simultaneously can strengthen the
diagnostic capability and clinical applicability of these imaging
technologies. In this study, we used a long scan time due to
the extensive research protocols included. In a clinical setting,
the tracer can be manually injected before the patient enters the
PET/MRI system, with a protocol tailored for a shorter scan time.
This study has some limitations. We did not examine
the reproducibility of the imaging techniques, for example
by performing MRSI and/or PET twice. The patient cohort
consisted of only 19 patients, however, all with high-risk prostate
cancer. The high-risk tumors are large and aggressive, thus
it remains to evaluate the diagnostic performance of these
imaging modalities in a larger patients cohort and lower grade
cancers. We only included 23% of the available spectroscopic
voxels based on quality criteria. This relatively low number
illustrates limitations of the use of the current PRESS MRSI
protocol. Spatial localization with conventional PRESS pulses
can cause the presence of large residual lipid signals. Moreover,
unsupervised automated shimming of the prostate can result
in suboptimal linewidths of the signals and suboptimal water
and lipid suppression in the spectra, which can be improved
by better shimming algorithms or manual re-adjustment after
the automated shim. More advanced prostate MRSI sequences
(39) improves localization and increases the number of voxels
with sufficient spectral quality. Quality control of the spectra,
either automated or visual, remains essential. The neighboring
voxels in both MRSI and PET data are not fully independent
measurements, because of the post-acquisition interpolation.
Although the number of MRSI voxels with sufficient SNR
was relatively low, the distribution between healthy, BPH, and
tumor was adequate enough to explore preliminary associations
between MRSI visible metabolites and uptake of the amino acid
analog 18F-fluciclovine, based on a simultaneous MRSI and PET
examination. The results from ROC analysis show that neither
MRSI nor PET performed better than the other technique alone
in distinguishing tumor voxels from other voxels (healthy and
BPH), but their combination performs significantly better than
any modality alone.
CONCLUSION
Simultaneous acquisition of 18F-fluciclovine PET and MRSI is
feasible in patients with prostate cancer, and showed a significant
correlation between both SUVmean and SUVmax and the CSC/C
ratio. A combination of the imaging outcomes derived from
the integrated PET/MRSI modalities can improve the diagnostic
accuracy of assessing prostate cancer lesions.
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